Notably, the antibodies effectively targeted leukemic stem cells in bone marrow samples and mouse models, which Flynn noted as “critical” because a handful of leukemia stem cells can ...

AML originates from a rare population of cells, termed leukemic stem cells (LSCs) or leukemia-initiating cells, which are capable of self-renewal, proliferation and differentiation into malignant ...

Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models. Science Translational Medicine , 2024; 16 (757) DOI: 10.1126/scitranslmed ...

Acute myelogenous leukemia, or AML, remains one of the most aggressive blood cancers. Each year, around 44,000 people in the U.

All the patients in the phase 2 study received cyclophosphamide, tacrolimus and mycophenolate mofetil for graft-vs-host ...

Congratulations to Emeline Boet (PhD Tamburini's group), winner of the poster session held at the CRTOH retreat on May 26-27, 2025 in the Post Doc Category.

First patient dosed with Debiopharm's first-in-class CD37 targeted antibody drug conjugate (ADC) in a Phase 1/2, multicenter, open-label trial, for patients with acute myeloid leukemia (AML) Debiophar ...